Thomas Sciascia, M.D.

Thomas Sciascia, M.D.

Chief Scientific OfficeratTrevi Therapeutics· In proxies 2022–2023

Pay in FY2023+69% from the year before · Trevi Therapeutics stock -30.6% the same year

Thomas Sciascia, M.D. was paid $977.1K in FY2023 (Dec), up 69%. Trevi Therapeutics stock fell 30.6% that year.

Pay$100 in the stock at the end of FY21 → $171
Pay is from the Summary Compensation Table of each Trevi Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Trevi TherapeuticsPublic company · 4 yr
    • Chief Scientific Officer2022 – Present · 4 yrStock in role +1,784%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?